<DOC>
	<DOCNO>NCT00645580</DOCNO>
	<brief_summary>In study aim examine effect SSRI augmentation negative symptom cognitive function schizophrenia patient well examine effect SSRI augmentation RNA protein product peripheral mononuclear cell ( PMC ) . Finally , aim relate change PMC element change clinical symptom cognitive function . Our study hypotheses SSRI augmentation anti-psychotic treatment schizophrenia patient improve negative symptom well cognitive symptom improvement relate biochemical change identifiable PMC element .</brief_summary>
	<brief_title>Genetic Expression Schizophrenics Treated With SSRI Augmentation : Relationship Clinical Cognitive Function</brief_title>
	<detailed_description>Clinical study show add selective serotonin reuptake inhibitor ( SSRI ) antidepressants antipsychotic improve negative symptom schizophrenia patient unresponsive antipsychotic alone ( Silver Nassar , 1992 ; Spina et al. , 1994 ; Goff et al. , 1995 ) . However , effect SSRI augmentation cognitive impairment illness adequately test . The mechanism SSRI augmentation know focus research interest . We recently show animal , combine treatment SSRI antidepressant antipsychotic drug result biochemical change , different effect individual medication . Changes unique combine treatment find GABAergic component ( GABA-Aβ3 receptor , glutamic acid decarboxylase 67 PKCβ ( Chertkow et al. , 2005 ) ) change unique combine treatment find select area rat brain . Studies drug mechanism human utilized blood product PMC readily accessible may reflect molecular process central nervous system ( CNS ) schizophrenic patient ( Kronfol Remick , 2000 ; Avissar et al. , 2001 ; Ilani et al. , 2001 ; Rothermundt et al. , 2001 ) . In recent study ( Chertkow et al. , 2007 ) examine gene expression profile PMC 's antipsychotic-treated patient addition SSRI fluvoxamine , find mRNA expression chemokine receptor , IL8RA CCR1 , RGS7 significantly down-regulated follow fluvoxamine augmentation . Additionally , clinical assessment show improvement negative symptom follow combined treatment . These finding suggest gene expression change PMC 's may useful investigate mechanism drug action schizophrenia . In study examine RNA protein expression course fluvoxamine augmentation treatment . 15 chronic schizophrenic patient persistent negative symptom cognitive impairment despite adequate treatment participate . Fluvoxamine 100mg/day add treatment regimen continue 6 week . Clinical state assess use validate rating scale cognitive performance assess cognitive test battery . Blood sample take baseline 1 , 3 6 week . The PMC 's assayed use microarray , RT PCR proteomic technique . Changes RNA protein expression detect compare change clinical symptom cognitive function . Identification biochemical change relate augmentation treat relation symptomatic cognitive change major potential benefit study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Age 1865 A diagnosis schizophrenia ( DSMIVTR ) Antipsychotic dose unchanged least 2 week prior study SANS score &gt; = 3 least one global measure affective blunting , alogia avolition . Knowledge Hebrew Dementia serious neurological disorder History alcohol drug use Patients legal guardian Patients involuntarily hospitalize order district psychiatrist Use antidepressant within 1 month study Renal hepatic disorder Patients upper GI bleed Patients SIADH syndrome Pregnant woman Criteria cessation study initial commencement : Severe adverse event ( include GI , cardiovascular , neurologic , hematologic urologic severe adverse event ) Emergent suicidality Emergence hypomanic manic symptom If subject request stop</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>